↑ トップへ ← 戻る

 Drug(薬物リスト) ALL | DrugBank 

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

33 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   Barium  1件: Barium;   -   -   -   1件:
98
 2   Beclomethasone dipropionate  1件: Beclomethasone dipropionate;   D00689
 D07495 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   2件:
97,
98
 3   Bethanechol  1件: Bethanechol;   D01000   5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5   3件: Cholinergic synapse, Gastric acid secretion, Neuroactive ligand-receptor interaction   1件:
98
 4   Budesonide  39件: Budesonide; Budesonide ( zentacort capsules 3mg ); Methylprednisolone or budesonide; Budesonide (6 mg); Budesonide (9 mg); Budesonide 6 mg capsules, hard (bux-pvii prototype); Budesonide 9 mg capsules, hard (bux-pv); Budesonide 9 mg capsules, hard (bux-pvii prototype); Budesonide mmx 6 mg tablet; Budesonide mmx®; Budesonide mmx® 6 mg; Budesonide mmx® 9 mg; Budesonide-mmx; Budesonide-mmx®; Budesonide-mmx® 6 mg; Budesonide-mmx® 9 mg; Budesonide-mmx™; Combination oral budesonide and rectal hydrocortisone; 0.5 mg budesonide effervescent tablet for orodispersible use; 1 mg budesonide effervescent tablet for orodispersible use; 1mg budesonide effervescent tablet for orodispersible use; 2mg budesonide effervescent tablet for orodispersible use; Budesonide 0.5mg orodispersible tablet twice daily; Budesonide 1mg orodispersible tablet twice daily; Budesonide [0.4mg/ml] viscous suspension; Budesonide oral suspension; Budesonide oral suspension [0.2 mg/ml]; Budesonide plus prevacid; Inhaled/swallowed budesonide; Oral budesonide; Oral budesonide suspension (mb-9); Oral budesonide suspension (obs); Oral viscous budesonide; Oral viscous budesonide (ovb); Viscous/swallowed budesonide; Budesonide/formoterol; Formoterol/budesonide; Budesonide-formoterol single inhaler; High dose of budesonide;   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   10件:
66,
85,
93,
94,
95,
96,
97,
98,
228,
299
 5   Cromoglicic acid  0件:   D00526
 D07753 
 -   -   2件:
85,
98
 6   Dexlansoprazole  1件: Dexlansoprazole;   D08903   2件: ATP4A, ATP4B   2件: Collecting duct acid secretion, Gastric acid secretion   1件:
98
 7   Dupilumab  3件: Dupilumab; Dupilumab (blinded); Dupilumab (open-label);   D10354   1件: IL4R   4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway   1件:
98
 8   Esomeprazole  3件: Esomeprazole; Esomeprazole 20 mg; Nexium (esomeprazole magnesium);   D01984
 D04056
 D07917
 D09339 
 2件: ATP4A, ATP4B   3件: Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation   6件:
6,
46,
86,
98,
298,
299
 9   Fluticasone  5件: Flovent (fluticasone propionate); Fluticasone; Fluticasone mdi; Fluticasone propionate; Swallowed fluticasone;   D07981   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   4件:
98,
228,
299,
306
 10   Fluticasone propionate  2件: Flovent (fluticasone propionate); Fluticasone propionate;   D01708   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   4件:
98,
228,
299,
306
 11   Honey  1件: Honey;   D06776   -   -   2件:
57,
98
 12   Infliximab  66件: Infliximab; Infliximab [infliximab biosimilar 3]; Topical infliximab; Remicaide (infliximab); Abp 710 - biosimilar to infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 3 mg/kg; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-eu; Infliximab-pfizer; Innovator infliximab; Methotrexate + infliximab; Remicade (infliximab); Remicade® (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Intravitreal infliximab; 99m technetium infliximab; 99mtc-infliximab; Inflectra (infliximab); Adalimumab and infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Ct-p13 sc (infliximab); Infliximab (ifx alone); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab 20 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab-biosimilar; Infliximab-innovator; Cyclosporine vs infliximab; Infliximab (ifx); Adalimumab, etanercept, golimumab or infliximab; Infliximab (bcd-055); Infliximab and mtx;   D02598   1件: TNF   9件: Adipocytokine signaling pathway, Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), MAPK signaling pathway, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   23件:
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
85,
95,
96,
97,
98,
162,
164,
269,
271
 13   Lansoprazole  5件: Lansoprazole; Lansoprazole, clarithromycin, amoxycillin; Dexlansoprazole; Treat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms; Lansoprazole, amoxicillin, clarithromycin;   D00355   2件: ATP4A, ATP4B   2件: Collecting duct acid secretion, Gastric acid secretion   6件:
63,
71,
98,
166,
222,
299
 14   Losartan  8件: Losartan; Losartan bluefish 50 mg; Sildenafil and losartan; Losartan potassium; Losartan and atenolol or propranolol; Losartan potasico; Lisinopril, losartan, and atorvastatin; Losartan tablets & qingremoshen granule;   D00357
 D08146 
 1件: AGTR1   4件: Adrenergic signaling in cardiomyocytes, Neuroactive ligand-receptor interaction, Renin-angiotensin system, Vascular smooth muscle contraction   18件:
13,
17,
19,
46,
58,
66,
67,
85,
96,
97,
98,
113,
164,
167,
179,
215,
222,
299
 15   Mepolizumab  5件: Mepolizumab; Sb-240563 (mepolizumab); Mepolizumab 100 mg; Mepolizumab 300 mg; Mepolizumab (a-il-5 antibody);   D04923   1件: IL5   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   4件:
44,
45,
98,
162
 16   Methamidophos  0件:   -   -   -   12件:
2,
11,
13,
19,
46,
49,
58,
70,
85,
98,
298,
300
 17   Mometasone furoate  0件:   D00690   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
98
 18   Montelukast  8件: Montelukast; Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; 5 mg montelukast; Montelukast/ singulair; Montelukast sodium; Montelukast teva; Singulair (montelukast sodium);   D00529
 D08229 
 1件: CYSLTR1   2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction   5件:
13,
46,
85,
98,
228
 19   Nitric Oxide  11件: Nitric oxide; Inhaled nitric oxide; Inhaled nitric oxide - 30 mcg/kg ibw/hr; Inhaled nitric oxide 5,10,15 mcg/kg ibw/hr; Inhaled nitric oxide 75 mcg/kg ibw/hr; Inhaled nitric oxide & inopulse delivery; Nitric oxide for inhalation; Nitric oxide generated by the geno nitrosyl delivery system; Nitric oxide plus oxygen; Nitric oxide supplement; Nitric oxide 160 ppm;   D00074   -   -   7件:
46,
85,
86,
98,
251,
294,
299
 20   Omalizumab  3件: Omalizumab; Omalizumab (xolair); Rituximab combined with omalizumab;   D05251   1件: FCER1A   2件: Asthma, Fc epsilon RI signaling pathway   6件:
53,
65,
98,
162,
226,
299
 21   Omeprazole  19件: Clartihromycin, amoxicillin, and omeprazole; Esomeprazole; Omeprazole; Dimebon + omeprazole; Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Diclofenac + omeprazole; Esomeprazole 20 mg; Naproxen 500 mg tablets (pn 200 minus omeprazole); Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); Omeprazole 20mg; Omeprazole (uk licensed generic product); Omeprazole 20 mg; Omeprazole 40 mg; Rifaximin+omeprazole+miralax; Omeprazole 20mg bid; Omeprazole magnesium; Omeprazole rectally 1mg/kg; Nexium (esomeprazole magnesium); Omeprazole 40mg capsule;   D00455
 D01207
 D05259
 D05261 
 2件: ATP4A, ATP4B   2件: Collecting duct acid secretion, Gastric acid secretion   15件:
6,
8,
13,
46,
51,
85,
96,
97,
98,
225,
271,
282,
294,
298,
299
 22   Potassium  5件: Dipotassium salt; Potassium; Potassium supplement; Losartan potassium; Potassium sparing diuretic;   D08403   -   -   9件:
46,
66,
67,
98,
115,
167,
179,
215,
235
 23   Propofol  3件: Propofol; Propofol-lipuro; Intubated with propofol (ip);   D00549   16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   2件: GABAergic synapse, Neuroactive ligand-receptor interaction   8件:
6,
21,
22,
34,
46,
84,
98,
296
 24   Reslizumab  1件: Reslizumab;   D08985   1件: IL5   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   3件:
44,
45,
98
 25   Sevoflurane  3件: Sevoflurane; Intubated with sevoflurane (is); Sevoflurane anesthetics;   D00547   -   -   5件:
6,
21,
22,
98,
296
 26   Sirolimus  16件: Sirolimus; Temsirolimus; Temsirolimus tablets; Sirolimus 2 mg; Skincerity plus sirolimus/rapamycin; Skinercity plus sirolimus/rapamycin; Sirolimus (formerly known as rapamycin); Sirolimus 2%; Sirolimus, 2%; Rapamycin, sirolimus; Sirolimus and hydroxychloroquine; Sirolimus 0.2%; Sirolimus 0.4%; Sirolimus 0,1% crème; Sirolimus oral liquid product 1mg/ml; Topical 0.1% sirolimus;   D00753   1件: MTOR   2件: Pathways in cancer, mTOR signaling pathway   36件:
2,
13,
15,
17,
34,
35,
36,
46,
49,
51,
60,
61,
62,
63,
65,
66,
67,
85,
86,
89,
96,
98,
137,
157,
158,
192,
222,
256,
277,
278,
279,
280,
281,
283,
285,
331
 27   Sucralfate  1件: Sucralfate;   D00446   -   -   1件:
98
 28   Technetium Tc-99m  0件:   -   -   -   1件:
98
 29   Vitamin D  31件: 10000iu vitamin d; 19 nor vitamin d; 25oh-vitamin d; 5000iu vitamin d; Cholecalciferol, vitamin d3; Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Verum arm receiving vitamin d oil; Vitamin d; Vitamin d3; Alendronate versus alfacalcidol (1-alpha oh vitamin d); Vitamin d in arm b; Vitamin d 25(oh)d; Vitamin d3 400 iu; Vitamin d3 6000 iu; Vitamin d3 3000 ui daily; Vitamin d3 4000 ui daily; Vitamin d3 800 ui/day then 800 ui/day; Vitamin d3: 3000 or 4000 ui/day then 2,000 ui/day; High-dose vitamin d (2000 iu per day); Standard-dose vitamin d (400iu per day); Vitamin d 100ug; Vitamin d 10ug; 25-hydroxyvitamin d3; Cholecalciferol (vitamin d3); D6-25-hydroxyvitamin d3; Ergocalciferol (vitamin d2); High-dose vitamin d3; Supplementation with vitamin d2/d3; Vitamin d oil; Vitamin d powder; Vitamin d2;   -   -   -   18件:
13,
19,
41,
46,
49,
50,
68,
93,
95,
96,
98,
179,
222,
228,
235,
274,
298,
299
 30   Vonoprazan  1件: Vonoprazan;   -   -   -   2件:
63,
98
 31   Wheat  1件: Wheat;   D06902   -   -   2件:
98,
266
 32   Xanthan gum  1件: Xanthan gum;   D06333   -   -   1件:
98
 33   Xylose  1件: Xylose;   D06346   -   -   1件:
98

先頭へ